Overview of Severin

Quick Facts

Property	Description
Active ingredient	Nimesulide
Form	Tablet, Granules for oral suspension
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose	Relief of pain and inflammation, fever reduction
Origin	Synthetic

Severin is a widely recognized brand name for a synthetic medication whose active ingredient is Nimesulide, belonging to the family of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is primarily used to provide relief from pain and inflammation by targeting key biological processes in the body.

What Pharmacological Class Does Severin Belong To?

Severin belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and is pharmacologically defined as a preferential cyclooxygenase-2 (COX-2) inhibitor. This mechanism is clinically recognized for providing effective relief while influencing the body’s inflammatory pathways. This means the medication works by interfering with the body's inflammatory response, specifically by reducing the production of chemical messengers called prostaglandins that trigger pain and swelling. The drug is classified as a single-ingredient product, with Nimesulide being the sole active substance responsible for its pharmacological effects.

Composition, Origin, and Available Forms

The medication's active core is Nimesulide, a chemical compound identified as a sulfonanilide derivative, confirming its entirely synthetic origin. Severin is manufactured for systemic oral administration and is commonly available in solid oral preparations, primarily as tablets or as granules for preparing an oral suspension. The availability of granules for suspension is a differentiating factor, offering an alternative form for patients who may find swallowing tablets challenging. These established forms allow for the precise delivery and absorption of the active ingredient into the bloodstream, facilitating its systemic action.

General Purpose: Relief of Pain and Inflammation

The general purpose of Severin is to achieve effective analgesia (pain relief) and to help reduce inflammation and fever (antipyresis) by addressing the underlying cause of discomfort. Nimesulide is categorized as an analgesic and anti-inflammatory agent. This confirmation establishes the drug's role in managing typical discomforts associated with inflammatory conditions, such as reducing swelling and soothing pain. As an NSAID, its action is focused on modulating the processes that contribute to inflammatory conditions, providing relief where pain, swelling, or elevated temperature is present.

What side effects are possible with Severin?

Official Classification of Possible Side Effects

The safety profile of Severin, which contains the active ingredient Nimesulide, is officially categorized based on frequency and the affected body system, as established in regulatory documents like the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

Adverse reactions are grouped into System-Organ Classes (SOCs), with the most commonly affected systems including Gastrointestinal disorders, Hepatobiliary disorders, and Skin and subcutaneous tissue disorders.

Frequency Category	Representative Adverse Reactions
Common (ge 1/100)	Diarrhoea, Nausea, Vomiting, Elevated liver enzymes
Uncommon (ge 1/1,000)	Dizziness, Hypertension, Gastrointestinal haemorrhage, Rash
Rare to Very Rare (< 1/1,000)	Anaphylaxis, Thrombocytopenia, Severe skin reactions, Fulminant Hepatitis

Serious Adverse Reactions and Safety Constraints

The regulatory label identifies specific serious adverse reactions (SARs) that, while often reported as rare, are clinically significant. These include Fulminant Hepatitis (a severe liver reaction), Gastrointestinal Ulceration and Perforation, and life-threatening skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety documents impose specific restrictions: treatment duration is limited to a maximum of 15 days for any single course of therapy to minimize risk, and the drug is contraindicated in patients with severe hepatic impairment, severe renal impairment, and during the third trimester of pregnancy. Furthermore, the risk of serious hepatic events is noted to be more likely to occur early in the course of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Severin requires immediate medical attention and expert clinical management. The official regulatory profile for the active ingredient, Nimesulide, documents that acute ingestion may initially present with common signs such as nausea, vomiting, and epigastric pain. Central Nervous System (CNS) manifestations, including drowsiness and lethargy, are also documented in overdose cases.

The primary concern is the potential for severe, life-threatening complications affecting major organ systems. Documented severe outcomes include acute renal failure and severe hepatic injury, such as fulminant hepatitis and liver failure. Massive ingestion can lead to escalation of effects, including seizures or coma. If any signs compatible with liver injury, such as persistent vomiting, abdominal pain, or dark urine, are experienced, the product must be discontinued immediately and urgent help sought.

Treatment for overdose is strictly symptomatic and supportive, as no specific antidote is known. Hospital observation is required, involving the continuous monitoring of vital signs, liver function tests, and renal function to manage end-organ damage effectively. Regulatory sources note that elderly patients are particularly vulnerable to severe adverse effects and require intensified clinical monitoring following any overdose event.

Therapeutic Uses of Severin

What Severin Treats: Main Uses and Benefits

Severin (Nimesulide) is commonly used to help with symptomatic relief for acute, painful, and inflammatory conditions in adults and adolescents over 12 years old. Common use includes acute pain and primary dysmenorrhoea, relevant in contexts involving heightened systemic burden. It is applied across domains where additional symptomatic support is needed, helping patients cope more steadily with difficult episodes.

Quick Fact: Relief for Pain and Inflammation

Context	Symptom Management Focus
Acute Injury	Helps with symptoms related to physical discomfort from soft-tissue injuries like sprains and strains.
Post-Procedural	Applied in scenarios where additional management of discomfort is required, such as post-operative pain.
Cyclical Pain	Relevant for easing acute discomfort of primary dysmenorrhoea.
Joint Flare-ups	Used for managing symptoms that become more disruptive during flare-ups of painful osteoarthritis.

This medication is applied in situations where symptoms appear suddenly or intensify quickly, relevant when supportive symptom management is appropriate. The main conditions it is commonly used to help with include symptomatic relief relevant in conditions characterized by periods of heightened symptoms, such as acute episodes of osteoarthritis, discomfort following soft-tissue injuries, post-operative pain, and the acute, cyclical pain of primary dysmenorrhoea.

“Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.”

Furthermore, it is commonly used to help with symptoms related to systemic imbalance, such as fever, and may assist with improved day-to-day comfort during symptomatic periods. This provides support that helps ease the overall symptom burden.

Regulatory References

European Medicines Agency (EMA) Nimesulide Referrals

Eligibility and Restrictions for Use

Who Can and Cannot Use Severin (Nimesulide)?

Regulatory authorities strictly define the eligible population for Severin, primarily restricting its use as a second-line treatment for adults and adolescents over 12 years of age for a maximum of 15 days.

Contraindications

Use of Severin is contraindicated (prohibited) in numerous populations, including:

Age-Based: Children under 12 years.
Organ Status: Patients with any degree of hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min).
Cardiovascular/Gastrointestinal: Patients with severe heart failure, active gastric or duodenal ulcer, or a history of cerebrovascular or other active bleeding disorders.
History/Hypersensitivity: Individuals with a history of hepatotoxic reactions to nimesulide or hypersensitivity to other NSAIDs.

Restricted Eligibility Status

Category	Official Regulatory Status
Age Groups	Eligible for adults and adolescents from 12 to 18 years.
Pregnancy/Lactation	Contraindicated in the third trimester of pregnancy and during breastfeeding.
Organ Function	Permitted with caution in mild to moderate renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific interaction constraints for Severin (Nimesulide) concerning co-administered medicinal products and substances.

Interaction Classifications

The most significant restrictions are driven by additive risk and pharmacokinetic modulation.

Interaction Type	Interacting Agent	Official Constraint Description
Contraindicated Combination	Other NSAIDs	Co-administration is formally prohibited.
Contraindicated Combination	Potentially Hepatotoxic Substances (e.g., Paracetamol)	Co-administration is prohibited due to the risk of cumulative hepatic adverse effects.
Not Recommended Combination	Anticoagulants (e.g., Warfarin) and Aspirin	Co-administration is not recommended due to an increased risk of bleeding complications (pharmacodynamic effect).
Metabolic (CYP2C9)	CYP2C9 Substrates	Severin is a documented inhibitor of the CYP2C9 enzyme, which may lead to increased plasma exposure of certain co-administered drugs.
Exposure Modification	Lithium	Requires close monitoring of lithium plasma levels due to the potential for increased exposure.
Pharmacodynamic	Loop Diuretics (e.g., Furosemide)	May cause a transient decrease of the diuretic effect and reduction in the diuretic's cumulative excretion.

Population-Specific Cautions

Caution is specifically required when co-administering Severin with Loop Diuretics in patients with pre-existing renal or cardiac impairment, as this interaction may result in the deterioration of renal function. The use of excess alcohol or in patients with a history of alcoholism is formally contraindicated. These interaction statements dictate the mandatory constraints for the safe use of Severin.

Mechanism of Action

Targeted Inhibition of the COX-2 Enzyme

Severin's mechanism centers on the preferential, reversible inhibition of the Cyclooxygenase-2 ( COX-2) enzyme, which is responsible for the accelerated synthesis of inflammatory mediators at sites of local inflammatory response. This action modifies the early molecular steps of the Arachidonic Acid Cascade, thereby engaging a mechanism that suppresses heightened enzyme-mediated signaling.

Modulation of the Prostaglandin Biosynthesis Pathway

The enzymatic blockade results in the direct suppression of Prostaglandin E2 ( PGE2) biosynthesis, a key chemical mediator in nociception and fever induction. Reducing the concentration of PGE2 decreases the effect of heightened mediator activity, leading to consequent shifts in signaling that attenuate the inflammatory process and reduce the sensitization of peripheral nociceptors.

Attenuation of Central and Peripheral Signals

The mechanism influences targeted pathways by acting both peripherally at the site of eicosanoid synthesis and centrally in the brain's thermoregulatory center. This dual-level action modifies early molecular steps that shape systemic physiological outcomes, resulting in the reversion of the elevated thermoregulatory set-point and a decrease in nociceptor sensitization.

Dosage and Administration Information

Instruction Map: How to use Severin — Official Administration Guidelines

Severin is intended for systemic oral administration, available in forms such as the 100 mg tablet or granules for oral suspension.

Element	Instruction
Dosing Schedule	The standard single dose is 100 mg. The maximum dose permitted in a 24-hour period is 200 mg.
Frequency	Twice daily (bid), maintaining a 12-hour interval between doses.
Timing in relation to meals	The medication is officially instructed to be taken after meals.
Course Duration	The maximum duration of a single treatment course is strictly limited to 15 days. Treatment should be for the shortest possible duration.

Procedural and Usage Boundaries

Classification	Pattern
Use-Context Constraint	Designated for use only as a second-line treatment.
Age-Group Rule	Use is limited to adolescents 12 years of age and older.
Special Boundary	Not indicated for use in patients with severe hepatic impairment or severe renal impairment.
Missed-Dose Rule	Do not take a double dose to compensate for a forgotten dose.

Connection to the Overall Use Protocol

The official instructions establish a structured, time-bound protocol, defining a fixed oral dose of 100 mg to be taken twice daily for a maximum of 15 days. This fixed schedule and duration limit confine the usage pattern, ensuring administration occurs after meals and is reserved for second-line use, while also confirming that standard adult doses apply to older adults.

Recent Clinical Evidence

Research evidence / Overview of studies for Severin

This section summarizes the structure of the official research studies that have been conducted for Severin (Nimesulide), detailing the study designs, the outcomes researchers evaluated, and the known limitations in the evidence landscape, as reported by authoritative scientific sources.

Evidence for use in Acute Pain Relief

Research has primarily used short-term Randomized Controlled Trials (RCTs) and scientific Meta-analyses in research exploring symptom patterns related to acute physical discomfort, such as pain related to soft-tissue injuries or following dental procedures. These trials were applied in studies examining how symptoms change over time and how measurements of patient-reported discomfort changed over time.

In these research scenarios, the studies monitored outcomes related to physical discomfort using standardized scales, and research highlights changes measured during the short study period. Findings describe patterns observed in the studies where the measurements of pain intensity change were compared against both inactive placebo and other active medications. A key uncertainty is that all efficacy data are restricted to short-term use only, reflecting a regulatory requirement that limits the allowed treatment duration.

Evidence for use in Primary Dysmenorrhoea

The clinical evaluation for the acute, cyclical pain associated with primary dysmenorrhoea has also relied on Randomized Controlled Trials. These studies were applied in research contexts involving fluctuating or unstable symptoms that occur during the menstrual cycle. In these trials, studies monitored patient-reported outcomes describing perceived discomfort and the severity of associated symptoms.

Findings describe patterns observed when changes in patient-reported discomfort were compared against other comparator medications. Findings help contextualize how patients reported their experience during episodes where symptoms become more noticeable. Research is focused narrowly on the short-term relief of acute episodes, and the evidence base does not provide insight into long-term outcomes or the management of continuous or chronic discomfort.

The Context of Osteoarthritis Research

For completeness, Nimesulide was evaluated in medium-term clinical trials in the past for its use in painful osteoarthritis, exploring outcomes reflecting daily functioning and pain assessment. However, the evidence derived from these settings is now superseded by regulatory restrictions. Major health authorities prohibit the use of Nimesulide for this chronic condition. This restriction relates to the unacceptable risk associated with the long-term exposure necessary to treat a chronic condition. The existing evidence for Osteoarthritis is solely for historical context.

Frequently Asked Questions (FAQ)

Common questions about Severin (FAQ)

Q: What is the main reason doctors prescribe Severin?

According to the official product information, Severin is indicated for two main therapeutic uses. It is prescribed for the treatment of acute pain that comes on suddenly and lasts a short time, and it is also indicated for the symptomatic treatment of primary dysmenorrhoea, which is acute menstrual pain.

Q: How quickly does Severin usually start to have an effect?

The official product information notes that effects related to pain relief are generally observed shortly after oral administration. Regulatory studies indicate the onset of pain relief is typically reported to occur within about 15 minutes.

Q: Is it normal to feel a bit dizzy when first starting Severin?

Yes, regulatory documents list dizziness and somnolence (drowsiness) as potential, though uncommon, side effects of the medication. Experiencing these effects does not happen to all users, but they are noted in the official safety data.

Q: Does Severin cause weight gain, or is that a common myth?

The official product information notes that fluid retention is a listed side effect, which can sometimes lead to edema (swelling). This fluid buildup is what may cause some fluctuation in body weight, and this potential effect is documented in the regulatory safety data.

Q: What are the most common side effects reported by people taking Severin?

Based on regulatory data, the most common side effects reported by patients in clinical trials include issues like diarrhoea, nausea (feeling sick), and vomiting. These effects are generally reported to be mild, but patient experience may vary.

Q: Does Severin affect my ability to drive or operate machinery?

Official warnings state that Severin has not been specifically studied for its effect on driving ability. However, if users experience side effects like dizziness, vertigo, or somnolence (drowsiness), regulatory documents caution that individuals must consider the impact on their ability to drive or operate machinery.

Q: Is Severin safe for use during pregnancy, according to official warnings?

Official warnings regarding the use of Severin during pregnancy state that its use is contraindicated (not allowed) during the third trimester of pregnancy. Like other medicines in its class (NSAIDs), it is generally not recommended after 20 weeks of gestation due to potential fetal risks.

Q: What should I do if a side effect of Severin becomes bothersome?

The regulatory guidance states that patients who experience symptoms consistent with severe adverse effects, such as a hepatic injury (liver damage), should discontinue treatment. The product information advises seeking consultation from a healthcare professional immediately upon stopping the medication.

Q: Are there any known interactions between Severin and herbal supplements?

Official drug labels and regulatory documents typically focus on interactions with other prescribed and over-the-counter medicines. Specific interactions with a comprehensive list of herbal supplements are generally not detailed in the core regulatory safety data.

Q: Has the research on Severin involved a large number of participants?

The safety evaluation relies on data from controlled clinical trials that included approximately 7,800 patients. This data base provides the foundation for the safety profile summarized in regulatory documents.

Q: How long does Severin typically stay in the body after the last dose?

Regulatory documents describe the pharmacokinetics, or how the body processes the medicine. The terminal elimination half-life (the time it takes for half the drug to be removed from the body) of the active compound is stated to be approximately 1.8 to 4.7 hours.

Q: Is Severin a type of steroid?

No, Severin is not a steroid. Official pharmacological classification places it in the drug class known as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its action involves regulating inflammatory processes through a specific enzymatic pathway.

Q: Does Severin affect blood sugar levels?

Official drug interaction data indicates that Severin can interact with certain anti-diabetic medications. When combined with specific anti-diabetic drugs, it carries a reported risk of increasing the chance of hypoglycemia (low blood sugar).

Q: Can I take Severin if I am lactose intolerant or have other allergies?

Regulatory information indicates that the drug is contraindicated (should not be used) in patients who have a known hypersensitivity or allergic reaction to the active substance or to any of the excipients (inactive ingredients). Patients with known intolerances or allergies are directed to review the full list of inactive ingredients.

Q: Can taking Severin cause sleep problems or insomnia?

Official side effect listings include somnolence (drowsiness) as a potential effect, which is related to changes in sleep/wakefulness. Like many medicines, it can sometimes affect the normal sleep cycle, but this side effect is typically uncommon.

Q: Are there specific instructions for what to do if an allergic reaction occurs?

Yes, the product information lists serious adverse reactions like anaphylactic shock (a severe whole-body allergic reaction) and severe skin reactions as potential, though rare, outcomes. These conditions are identified as requiring immediate professional medical attention.

Q: How is Severin approved for use by regulatory bodies like the FDA or EMA?

The regulatory approval for Severin is a rigorous process conducted by authorities like the European Medicines Agency (EMA). This process requires that the drug meets defined standards for its quality, established safety profile, and demonstrated efficacy (effectiveness) in clinical studies.

Q: Is Severin related to any other drug I might already know?

Severin belongs to the drug class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is a common class of medication that includes many other compounds used for pain relief and anti-inflammatory purposes.

Q: Do studies suggest Severin is more suitable for certain patient groups?

Official indications limit who can use the medicine, based on clinical research. It is specifically indicated only for adolescents 12 years of age and older, and one of its key therapeutic indications is primary dysmenorrhoea, which is a condition specific to women.

Q: What is the most serious potential side effect listed for Severin?

The official product information lists several serious risks. Rarely, the drug has been associated with serious hepatic reactions (liver problems), including very rare fatal cases, as well as severe gastrointestinal bleeding or perforation.

Q: What is the chemical name of Severin?

According to the official drug naming conventions recognized internationally, the International Non-Proprietary Name (INN) of the active ingredient in Severin is Nimesulide.

Q: Are the side effects of Severin usually temporary or do they last a long time?

Official warnings about severe adverse effects, such as hepatic injury, often note that these issues typically resolve after the patient stops taking the medication. This observation suggests that many adverse effects are temporary upon discontinuation of treatment.

How should Severin be stored and disposed of?

The following storage and disposal requirements are based on official regulatory labeling for the active ingredient, Carglumic Acid 200 mg Dispersible Tablets.

Official Storage and Stability

Condition	Requirement (Unopened Container)	Requirement (After First Opening)
Temperature	Does not require special storage conditions (ambient).	Store at room temperature; Do not refrigerate or freeze
Moisture Protection	None specified for unopened blister/container.	Keep container tightly closed to protect from moisture.
In-Use Stability	Not applicable.	Discard any unused tablets one month after first opening the container.

Child-Safety and Disposal

Child Protection: The high-density polyethylene container is supplied with a child-resistant cap and must be kept out of the sight and reach of children.
Disposal: The official documentation states there are no special requirements for the disposal of the unused product or waste material. Users should follow standard procedures for pharmaceutical disposal established by local and national regulations.

Severin